熱門資訊> 正文
Rapport Therapeutics将2.5亿美元的股票定价为每股26美元
2025-09-10 15:30
- Rapport Therapeutics (NASDAQ:RAPP) priced an underwritten public offering of 9.62M shares at a public offering price of $26.00 per share.
- The underwriters have a 30-day option to purchase up to an additional 1.44M shares.
- The gross proceeds from the offering are expected to be ~$250M.
- The offering is expected to close on or about September 11, 2025.
More on Rapport Therapeutics
- Rapport: Surging On Phase 2 Study Win - Full Approval Unlikely Before 2028
- Biggest stock movers Monday: RAPP, MCRB, SATS, QS, SMMT and more
- Rapport Therapeutics soars 23% on release of phase 2 data for seizure asset
- Seeking Alpha’s Quant Rating on Rapport Therapeutics
- Historical earnings data for Rapport Therapeutics
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
